C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register
(2019) In Diabetes Research and Clinical Practice 150. p.174-183- Abstract
Aims: To study the association between baseline level of C-peptide and all-cause death, cardiovascular death and cardiovascular complications among persons with newly diagnosed type 2 diabetes. Methods: The Skaraborg Diabetes Register contains data on baseline C-peptide concentrations among 398 persons <65 years with newly diagnosed type 2 diabetes 1996–1998. National registries were used to determine all-cause death, cardiovascular death and incidence of myocardial infarction and ischemic stroke until 31 December 2014. The association between baseline C-peptide and outcomes were evaluated with adjustment for multiple confounders by Cox regression analysis. Missing data were handled by multiple imputation. Results: In the imputed and... (More)
Aims: To study the association between baseline level of C-peptide and all-cause death, cardiovascular death and cardiovascular complications among persons with newly diagnosed type 2 diabetes. Methods: The Skaraborg Diabetes Register contains data on baseline C-peptide concentrations among 398 persons <65 years with newly diagnosed type 2 diabetes 1996–1998. National registries were used to determine all-cause death, cardiovascular death and incidence of myocardial infarction and ischemic stroke until 31 December 2014. The association between baseline C-peptide and outcomes were evaluated with adjustment for multiple confounders by Cox regression analysis. Missing data were handled by multiple imputation. Results: In the imputed and fully adjusted model there was a significant association between 1 nmol/l increase in C-peptide concentration and all-cause death (HR 2.20, 95% CI 1.49–3.25, p < 0.001, number of events = 104), underlying cardiovascular death (HR 2.69, 1.49–4.85, p = 0.001, n = 35) and the composite outcome of underlying cardiovascular death, myocardial infarction or ischemic stroke (HR 1.61, 1.06–2.45, p = 0.027, n = 90). Conclusions: Elevated C-peptide levels at baseline in persons with newly diagnosed type 2 diabetes are associated with increased risk of all-cause and cardiovascular mortality. C-peptide might be used to identify persons at high risk of cardiovascular complications and premature death.
(Less)
- author
- Pikkemaat, Miriam LU ; Andersson, Tobias ; Melander, Olle LU ; Chalmers, John ; Rådholm, Karin and Bengtsson Boström, Kristina LU
- organization
- publishing date
- 2019
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- C-peptide, Cardiovascular diseases, Cause of death, Cohort studies, Mortality, Type 2 diabetes mellitus
- in
- Diabetes Research and Clinical Practice
- volume
- 150
- pages
- 10 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:85063081718
- pmid:30878389
- ISSN
- 0168-8227
- DOI
- 10.1016/j.diabres.2019.03.014
- language
- English
- LU publication?
- yes
- id
- 93688e19-89d3-485b-82fa-5bb53c01fcd2
- date added to LUP
- 2019-03-27 13:36:01
- date last changed
- 2024-09-17 16:23:17
@article{93688e19-89d3-485b-82fa-5bb53c01fcd2, abstract = {{<p>Aims: To study the association between baseline level of C-peptide and all-cause death, cardiovascular death and cardiovascular complications among persons with newly diagnosed type 2 diabetes. Methods: The Skaraborg Diabetes Register contains data on baseline C-peptide concentrations among 398 persons <65 years with newly diagnosed type 2 diabetes 1996–1998. National registries were used to determine all-cause death, cardiovascular death and incidence of myocardial infarction and ischemic stroke until 31 December 2014. The association between baseline C-peptide and outcomes were evaluated with adjustment for multiple confounders by Cox regression analysis. Missing data were handled by multiple imputation. Results: In the imputed and fully adjusted model there was a significant association between 1 nmol/l increase in C-peptide concentration and all-cause death (HR 2.20, 95% CI 1.49–3.25, p < 0.001, number of events = 104), underlying cardiovascular death (HR 2.69, 1.49–4.85, p = 0.001, n = 35) and the composite outcome of underlying cardiovascular death, myocardial infarction or ischemic stroke (HR 1.61, 1.06–2.45, p = 0.027, n = 90). Conclusions: Elevated C-peptide levels at baseline in persons with newly diagnosed type 2 diabetes are associated with increased risk of all-cause and cardiovascular mortality. C-peptide might be used to identify persons at high risk of cardiovascular complications and premature death.</p>}}, author = {{Pikkemaat, Miriam and Andersson, Tobias and Melander, Olle and Chalmers, John and Rådholm, Karin and Bengtsson Boström, Kristina}}, issn = {{0168-8227}}, keywords = {{C-peptide; Cardiovascular diseases; Cause of death; Cohort studies; Mortality; Type 2 diabetes mellitus}}, language = {{eng}}, pages = {{174--183}}, publisher = {{Elsevier}}, series = {{Diabetes Research and Clinical Practice}}, title = {{C-peptide predicts all-cause and cardiovascular death in a cohort of individuals with newly diagnosed type 2 diabetes. The Skaraborg diabetes register}}, url = {{http://dx.doi.org/10.1016/j.diabres.2019.03.014}}, doi = {{10.1016/j.diabres.2019.03.014}}, volume = {{150}}, year = {{2019}}, }